ALT
Price
$5.62
Change
+$0.16 (+2.93%)
Updated
Jun 6, 04:59 PM (EDT)
Capitalization
455.82M
62 days until earnings call
NBY
Price
$0.59
Change
-$0.00 (-0.00%)
Updated
Jun 6, 04:29 PM (EDT)
Capitalization
3.43M
Interact to see
Advertisement

ALT vs NBY

Header iconALT vs NBY Comparison
Open Charts ALT vs NBYBanner chart's image
Altimmune
Price$5.62
Change+$0.16 (+2.93%)
Volume$74.73K
Capitalization455.82M
NovaBay Pharmaceuticals
Price$0.59
Change-$0.00 (-0.00%)
Volume$2K
Capitalization3.43M
ALT vs NBY Comparison Chart
Loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALT vs. NBY commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Buy and NBY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (ALT: $5.46 vs. NBY: $0.59)
Brand notoriety: ALT and NBY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 99% vs. NBY: 72%
Market capitalization -- ALT: $455.82M vs. NBY: $3.43M
ALT [@Biotechnology] is valued at $455.82M. NBY’s [@Biotechnology] market capitalization is $3.43M. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileNBY’s FA Score has 1 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • NBY’s FA Score: 1 green, 4 red.
According to our system of comparison, NBY is a better buy in the long-term than ALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 6 TA indicator(s) are bullish while NBY’s TA Score has 7 bullish TA indicator(s).

  • ALT’s TA Score: 6 bullish, 4 bearish.
  • NBY’s TA Score: 7 bullish, 2 bearish.
According to our system of comparison, NBY is a better buy in the short-term than ALT.

Price Growth

ALT (@Biotechnology) experienced а -2.67% price change this week, while NBY (@Biotechnology) price change was +6.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.92%. For the same industry, the average monthly price growth was +17.56%, and the average quarterly price growth was +3.51%.

Reported Earning Dates

ALT is expected to report earnings on Aug 07, 2025.

NBY is expected to report earnings on Apr 02, 2025.

Industries' Descriptions

@Biotechnology (+11.92% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALT($456M) has a higher market cap than NBY($3.43M). NBY YTD gains are higher at: -1.880 vs. ALT (-24.272). NBY has higher annual earnings (EBITDA): -6.52M vs. ALT (-94.81M). ALT has more cash in the bank: 132M vs. NBY (776K). NBY has less debt than ALT: NBY (1.26M) vs ALT (1.68M). NBY has higher revenues than ALT: NBY (13.8M) vs ALT (20K).
ALTNBYALT / NBY
Capitalization456M3.43M13,294%
EBITDA-94.81M-6.52M1,454%
Gain YTD-24.272-1.8801,291%
P/E RatioN/A0.02-
Revenue20K13.8M0%
Total Cash132M776K17,010%
Total Debt1.68M1.26M133%
FUNDAMENTALS RATINGS
ALT vs NBY: Fundamental Ratings
ALT
NBY
OUTLOOK RATING
1..100
44
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
13
Undervalued
PROFIT vs RISK RATING
1..100
90100
SMR RATING
1..100
9499
PRICE GROWTH RATING
1..100
6362
P/E GROWTH RATING
1..100
10053
SEASONALITY SCORE
1..100
19n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NBY's Valuation (13) in the Biotechnology industry is significantly better than the same rating for ALT (98) in the Miscellaneous Commercial Services industry. This means that NBY’s stock grew significantly faster than ALT’s over the last 12 months.

ALT's Profit vs Risk Rating (90) in the Miscellaneous Commercial Services industry is in the same range as NBY (100) in the Biotechnology industry. This means that ALT’s stock grew similarly to NBY’s over the last 12 months.

ALT's SMR Rating (94) in the Miscellaneous Commercial Services industry is in the same range as NBY (99) in the Biotechnology industry. This means that ALT’s stock grew similarly to NBY’s over the last 12 months.

NBY's Price Growth Rating (62) in the Biotechnology industry is in the same range as ALT (63) in the Miscellaneous Commercial Services industry. This means that NBY’s stock grew similarly to ALT’s over the last 12 months.

NBY's P/E Growth Rating (53) in the Biotechnology industry is somewhat better than the same rating for ALT (100) in the Miscellaneous Commercial Services industry. This means that NBY’s stock grew somewhat faster than ALT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALTNBY
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BFTIX61.21N/A
N/A
Baron Fifth Avenue Growth Instl
PROVX19.10N/A
N/A
Provident Trust Strategy
NRSRX49.82N/A
N/A
Neuberger Berman Sustainable Equity R6
OANLX79.55N/A
N/A
Oakmark Select Institutional
NSFKX13.11-0.02
-0.15%
Natixis Target Retirement 2050 N

ALT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALT has been loosely correlated with CRNX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ALT jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALT
1D Price
Change %
ALT100%
-0.55%
CRNX - ALT
48%
Loosely correlated
+0.59%
COGT - ALT
46%
Loosely correlated
+6.03%
XNCR - ALT
46%
Loosely correlated
+0.22%
VKTX - ALT
46%
Loosely correlated
+0.15%
CLDX - ALT
45%
Loosely correlated
-0.76%
More

NBY and

Correlation & Price change

A.I.dvisor indicates that over the last year, NBY has been loosely correlated with PRTG. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if NBY jumps, then PRTG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBY
1D Price
Change %
NBY100%
-1.22%
PRTG - NBY
38%
Loosely correlated
-3.46%
ALT - NBY
30%
Poorly correlated
-0.55%
ORMP - NBY
29%
Poorly correlated
-5.70%
PMN - NBY
26%
Poorly correlated
-4.56%
IMMP - NBY
25%
Poorly correlated
-1.21%
More